natgillin/translations-raw huggingface dataset:
After reconstitution with the solvent provided, each ml of the solution contains 0.25 mg cetrorelix.
Po rekonstituciji s priloženim vehiklom vsebuje en ml raztopine 0,25 mg cetroreliksa.
After reconstitution with the supplied solvent (0.234% sodium chloride solution), each vial contains 50, 100, 200, 400 or 600 IU/ml (see Table 1).
Po rekonstituciji s priloženim vehiklom (0,234-odstotna raztopina natrijevega klorida) ena viala vsebuje 50, 100, 200, 400 ali 600 i.e./ml (glejte preglednico 1).
After reconstitution with the supplied solvent (sodium chloride 9 mg/ml (0.9%) solution for injection) the prepared solution for injection contains 62.5, 125, 250, 375, 500 or 750 IU turoctocog alfa per ml respectively (based on the strength of turoctocog alfa, i.e.
Po pripravi s priloženim vehiklom (9 mg/ml (0,9 %) raztopina natrijevega klorida za injekcije) vsebuje pripravljena raztopina za injiciranje 62,5, 125, 250, 375, 500 ali 750 i.e. turoktokoga alfa na ml (na podlagi jakosti turoktokoga alfa, tj.
After reconstitution with water for injections the medicine must be used immediately and as a single use vial.
Po rekonstituciji z vodo za injekcije je treba zdravilo uporabiti takoj in kot vialo za enkratno uporabo.
After reconstitution with water for injections, the medicinal product must be used immediately and must be used as a single use vial.
Po rekonstituciji z vodo za injekcije je treba zdravilo uporabiti takoj in kot vialo za enkratno uporabo.
After reconstitution with water for injections, the reconstituted solution, if not used immediately, should be protected from direct sunlight, and stored refrigerated at 2C - 8C.
Po rekonstituciji z vodo za injekcije je treba pripravljeno raztopino – če ni uporabljena takoj – zaščititi pred neposredno sončno svetlobo in shraniti v hladilniku pri temperaturi od 2 do 8 C.
After reconstitution, 0.4 mL of suspension contains 4 mg somatropin (10 mg/mL).
Po rekonstituciji 0,4 ml suspenzije vsebuje 4 mg somatropina (10 mg/ml).
After reconstitution, 0.5 mL of suspension contains 10 mg somatropin (20 mg/mL).
Po rekonstituciji 0,5 ml suspenzije vsebuje 10 mg somatropina (20 mg/ml).
After reconstitution, 0.7 mL of suspension contains 7 mg somatropin (10 mg/mL).
Po rekonstituciji 0,7 ml suspenzije vsebuje 7 mg somatropina (10 mg/ml).
After reconstitution, 1 dose (0.5 ml) contains 5 micrograms of Neisseria meningitidis group A, C, W- 135 and Y polysaccharides.
Po rekonstituciji vsebuje 1 odmerek (0,5 ml) 5 mikrogramov polisaharidov Neisseria meningitidis skupin A, C, W-135 in Y.
After reconstitution, 1 dose (0.5 ml) contains:
Po pripravi cepiva 1 odmerek (0,5 ml) vsebuje:
After reconstitution, 1 dose (0.5 ml) contains:
Po rekonstituciji cepiva 1 odmerek (0,5 ml) vsebuje:
After reconstitution, 1 dose (0.5 ml) contains:
Po rekonstituciji en odmerek (0,5 ml) vsebuje:
After reconstitution, 1 dose (0.5 ml) contains:
Po rekonstituciji en odmerek cepiva (0,5 ml) vsebuje:
After reconstitution, 1 dose (0.5 ml) contains:
Po rekonstituciji vsebuje 1 odmerek (0,5 ml):
After reconstitution, 1 dose (0.5 ml):
1 odmerek (0,5 ml) po rekonstituciji:
After reconstitution, 1 dose (0.65 ml) contains: The active substance is:
Po rekonstituciji 1 odmerek (0,65 ml) vsebuje: Zdravilna učinkovina je:
After reconstitution, 1 dose (1 ml) contains:
Po rekonstituciji 1 odmerek (1 ml) vsebuje:
After reconstitution, 1 ml concentrate contains 1 mg topotecan.
Po pripravi 1 ml koncentrata vsebuje 1 mg topotekana.
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*
Po rekonstituciji 1 ml vsebuje 250 mikrogramov (8,0 milijonov i.e.) interferona beta 1-b*.
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*
Po rekonstituciji 1 ml vsebuje 250 mikrogramov (8,0 milijonov i.e.) interferona beta-1b*.
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*.
Po rekonstituciji 1 ml vsebuje 250 mikrogramov (8, milijonov i.e.) interferona beta 1-b*.
After reconstitution, 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b*.
Po rekonstituciji 1 ml vsebuje 250 mikrogramov (8,0 milijonov i.e.) interferona beta 1-b*.
After reconstitution, 1 ml of concentrate contains 24 mg docetaxel
Po pripravi vsebuje 1 ml koncentrata 24 mg docetaksela.
After reconstitution, 1 ml of concentrate contains 24 mg docetaxel.
Po pripravi vsebuje 1 ml koncentrata 24 mg docetaksela.
After reconstitution, 1 ml of concentrate contains 24 mg docetaxel.
Po pripravi vsebuje 1 ml koncentrata 24 mg/ml docetaksela.
After reconstitution, 1 mL of oral suspension contains 25 mg of aprepitant.
Po rekonstituciji 1 ml peroralne suspenzije vsebuje 25 mg aprepitanta.
After reconstitution, 1 ml of solution contains 10 mg of pegvisomant.* Excipient with known effect
1 ml pripravljene raztopine vsebuje 10 mg pegvisomanta.* Pomožna snov z znanim učinkom
After reconstitution, 1 ml of solution contains 10 mg pegvisomant
1 ml pripravljene raztopine vsebuje 10 mg pegvisomanta.
After reconstitution, 1 ml of solution contains 15 mg of pegvisomant.* Excipient with known effect
1 ml pripravljene raztopine vsebuje 15 mg pegvisomanta.* Pomožna snov z znanim učinkom
After reconstitution, 1 ml of solution contains 15 mg pegvisomant
1 ml pripravljene raztopine vsebuje 15 mg pegvisomanta.
After reconstitution, 1 mL of solution contains 2 mg of carfilzomib.
Po rekonstituciji 1 ml raztopine vsebuje 2 mg karfilzomiba.
After reconstitution, 1 ml of solution contains 20 mg of pegvisomant.* Excipient with known effect:
1 ml pripravljene raztopine vsebuje 20 mg pegvisomanta.* Pomožna snov z znanim učinkom
After reconstitution, 1 ml of solution contains 20 mg pegvisomant
1 ml pripravljene raztopine vsebuje 20 mg pegvisomanta.
After reconstitution, 1 ml of solution contains 25 mg of pegvisomant.* Excipient with known effect
1 ml pripravljene raztopine vsebuje 25 mg pegvisomanta.* Pomožna snov z znanim učinkom
After reconstitution, 1 ml of solution contains 25 mg pegvisomant
1 ml pripravljene raztopine vsebuje 25 mg pegvisomanta.
After reconstitution, 1 ml of solution contains 30 mg of pegvisomant.* Excipient with known effect
1 ml pripravljene raztopine vsebuje 30 mg pegvisomanta.* Pomožna snov z znanim učinkom
After reconstitution, 1 ml of solution contains 30 mg pegvisomant
1 ml pripravljene raztopine vsebuje 30 mg pegvisomanta.
After reconstitution, 1 ml of solution for infusion contains 2.5 mg temozolomide.
Po rekonstituciji 1 ml raztopine za infundiranje vsebuje 2,5 mg temozolomida.
After reconstitution, 1 ml of solution for intravenous injection contains 1 mg bortezomib.
Po rekonstituciji, 1 ml raztopine za intravensko injiciranje vsebuje 1 mg bortezomiba.
After reconstitution, 1 ml of solution for subcutaneous injection contains 2.5 mg bortezomib.
Po rekonstituciji, 1 ml raztopine za subkutano injiciranje vsebuje 2,5 mg bortezomiba.
After reconstitution, 1 mL of suspension contains 20 mg somatropin (20 mg/mL).
Po rekonstituciji 1 ml suspenzije vsebuje 20 mg somatropina (20 mg/ml).
After reconstitution, 1 ml of the solution contains 30 mg of ceftaroline fosamil.
Po rekonstituciji vsebuje 1 ml raztopine 30 mg fosamilceftarolina.
After reconstitution, 1 mL oral suspension contains 25 mg of aprepitant
Po rekonstituciji vsebuje 1 ml peroralne suspenzije 25 mg aprepitanta.
After reconstitution, 1dose (0.5 ml) contains (live, attenuated):
Po pripravi cepiva 1 odmerek (0,5 ml) vsebuje (živ, oslabljen):
After reconstitution, 1dose (0.65 ml) contains:
Po rekonstituciji 1 odmerek (0,65 ml) vsebuje:
After reconstitution, 1ml of concentrate contains 24 mg docetaxel (anhydrous).
Po pripravi vsebuje 1 ml koncentrata 24 mg docetaksela (brez vode).
After reconstitution, a deliverable volume of
Po pripravi vsebuje uporabna količina
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 micrograms of romiplostim (500 micrograms/ml).
Po pripravi vsebuje uporabna količina 0,5 ml raztopine 250 mikrogramov romiplostima (500 mikrogramov/ml).
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 micrograms of romiplostim (500 micrograms/ml).
Po pripravi vsebuje uporabna količina, ki je 0,5 ml, 250 mikrogramov romiplostima (500 mikrogramov/ml).
After reconstitution, a deliverable volume of 0.5 ml solution contains 250 µg of romiplostim (500 µg/ml).
Po pripravi uporabna količina 0,5 ml raztopine vsebuje 250 µg romiplostima (500 µg/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 micrograms of romiplostim (500 micrograms/ml).
Po pripravi vsebuje uporabna količina 1 ml raztopine 500 mikrogramov romiplostima (500 mikrogramov/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 micrograms of romiplostim (500 micrograms/ml).
Po pripravi vsebuje uporabna količina, ki je 1 ml, 500 mikrogramov romiplostima (500 mikrogramov/ml).
After reconstitution, a deliverable volume of 1 ml solution contains 500 µg of romiplostim (500 µg/ml).
Po pripravi uporabna količina 1 ml raztopine vsebuje 500 µg romiplostima (500 µg/ml).
After reconstitution, administer one dose (2 ml) of the vaccine by intramuscular (IM) injection.
Po rekonstituciji dajte en odmerek (2 ml) cepiva z intramuskularno (i.m.) injekcijo.
After reconstitution, chemical and physical in-use stability has been demonstrated for 24 hours when stored at room temperature.
Po rekonstituciji je zdravilo pri sobni temperaturi kemijsko in fizikalno stabilno 24 h.
After reconstitution, chemical and physical in-use stability has been demonstrated for 4 days at 2 to 8°C. The medicinal product is photosensitive and should be protected from light when not stored in the original carton.
Po rekonstituciji sta kemična in fizikalna stabilnost med uporabo dokazani za 4 dni pri temperaturi od 2 °C do 8 °C. Zdravilo je občutljivo za svetlobo in ga je treba zaščititi pred svetlobo, kadar ni shranjeno v originalni škatli.
After reconstitution, chemical and physical stability has been demonstrated for 30 hours up to 25ºC.
Po rekonstituciji je kemična in fizikalna stabilnost dokazana za 30 ur pri temperaturi do 25 ºC.
After reconstitution, chemical and physical stability has been demonstrated for 6 hours at 25°C and 24 hours at 5°C.
Po pripravi je kemična in fizikalna stabilnost dokazana za 6 ur pri temperaturi 25 C in 24 ur pri temperaturi 5 °C.
After reconstitution, chemical and physical stability has been demonstrated for 6 hours at 25C and 24 hours at 5C.
Po pripravi je kemična in fizikalna stabilnost dokazana za 6 ur pri temperaturi 25 C in 24 ur pri temperaturi 5 °C.
After reconstitution, dilute the product to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection.
Po pripravi morate raztopino razredčiti do 100 ml z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje ali s 5 % raztopino glukoze za injiciranje.
After reconstitution, dilute the product to 100 ml with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution for injection.
Po raztapljanju praška morate raztopino razredčiti do 100 ml z 9 mg/ml (0,9 %) raztopino natrijevega klorida za injiciranje ali s 5 % raztopino glukoze za injiciranje.
After reconstitution, do not store above 25°C. Do not freeze.
Po rekonstituciji shranjujte pri temperaturi do 25 °C. Ne zamrzujte.
After reconstitution, draw 1.0 ml from the vial into the syringe for the administration of 250 microgram Betaferon.
Za odmerjanje 250 mikrogramov zdravila Betaferon je treba po rekonstituciji potegniti 1 ml raztopine iz viale v brizgo.
After reconstitution, draw all the liquid (1 ml) from the vial back into the syringe for the administration of 30 micrograms AVONEX.
Za uporabo 30 g zdravila AVONEX po rekonstituciji potegnite vso tekočino (1 ml) iz viale nazaj v injekcijsko brizgo (oznaka na napolnjeni injekcijski brizgi).
After reconstitution, each dose of 71.4 microlitre contains 100 micrograms parathyroid hormone
Po pripravi en odmerek z 71,4 mikrolitri vsebuje 100 mikrogramov obščitničnega hormona.
After reconstitution, each dose of 71.4 microlitre contains 100 micrograms parathyroid hormone produced in Escherichia coli by recombinant DNA technology
Po rekonstituciji en odmerek z 71,4 mikrolitri vsebuje 100 mikrogramov obščitničnega hormona, ki je pridobljen v Escherichia coli s tehnologijo rekombinantne DNA.
After reconstitution, each ml contains 0.2 mg tasonermin.
Po pripravi vsebuje en ml 0,2 mg tasonermina.
After reconstitution, each ml contains 10 mg of infliximab.
Po rekonstituciji en ml raztopine vsebuje 10 mg infliksimaba.
After reconstitution, each ml contains 250 microgram (8.0 million IU) of recombinant interferon beta- 1b.
Po rekonstituciji vsebuje en ml 250 mikrogramov (8,0 milijonov i.e.) rekombinantnega interferona beta-1b.
After reconstitution, each ml contains 60 mg of vedolizumab.
Po rekonstituciji en ml vsebuje 60 mg vedolizumaba.
After reconstitution, each ml of concentrate contains 25 mg of belatacept.
Po pripravi raztopine en ml koncentrata vsebuje 25 mg belatacepta.
After reconstitution, each mL of concentrate contains 25 mg of elotuzumab.
Po rekonstituciji en ml koncentrata vsebuje 25 mg elotuzumaba.
After reconstitution, each ml of concentrate contains pixantrone dimaleate equivalent to 5.8 mg pixantrone.
Po rekonstituciji en ml koncentrata vsebuje 5,8 mg piksantrona v obliki piksantronijevega dimaleata.
After reconstitution, each ml of reconstituted suspension in the vial contains 0.08 mg of mifamurtide.
Po rekonstituciji en ml rekonstituirane suspenzije v viali vsebuje 0,08 mg mifamurtida.
After reconstitution, each ml of solution contains 80 mg rilonacept.
Po rekonstituciji vsebuje 1 ml raztopine 80 mg rilonacepta.
After reconstitution, each ml of suspension contains 0.08 mg of mifamurtide.
Po rekonstituciji en ml suspenzije vsebuje 0,08 mg mifamurtida.
After reconstitution, each mL of suspension contains 25 mg azacitidine.
Po rekonstituciji vsebuje vsak ml suspenzije 25 mg azacitidina.
After reconstitution, each ml of suspension in the vial contains 0.08 mg mifamurtide.
Po rekonstituciji en ml suspenzije v viali vsebuje 0,08 mg mifamurtida.
After reconstitution, each ml of the solution contains 150 IU follitropin alfa and 75 IU lutropin alfa per milliliter.
Po rekonstituciji vsak ml raztopine vsebuje 150 i.e. folitropina alfa in 75 i.e. lutropina alfa na mililiter.
After reconstitution, each ml of the solution contains 150 IU r-hFSH and 75 IU r-hLH per milliliter.
Po rekonstituciji vsak ml raztopine vsebuje 150 i.e. r-hFSH in 75 i.e. r-hLH na mililiter.
After reconstitution, each ml solution contains 0.2 mg tasonermin.
Po pripravi vsebuje en ml raztopine 0,2 mg tasonermina.
After reconstitution, each ml solution contains 2.5 mg porfimer sodium.
Po pripravi vsebuje vsak ml raztopine 2,5 mg/ml porfimer-natrija.
After reconstitution, each ml solution for infusion contains 2.5 mg of temozolomide.
Po rekonstituciji enega ml raztopine za infundiranje vsebuje 2,5 mg temozolomida.
After reconstitution, each ml suspension in the vial contains 0.08 mg mifamurtide.
Po rekonstituciji en ml suspenzije v viali vsebuje 0,08 mg mifamurtida.
After reconstitution, each vial contains 19 mg (0.8 mmol) sodium.
Po pripravi ena viala vsebuje 19 mg (0,8 mmol) natrija.
After reconstitution, each vial contains 5 mg of teduglutide in 0.5 ml of solution, corresponding to a concentration of 10 mg/ml.
Po rekonstituciji ena viala vsebuje 5 mg teduglutida v 0,5 ml raztopine, kar ustreza koncentraciji 10 mg/ml.
After reconstitution, filtering using the filter provided and further dilution, MEPACT is administered by intravenous infusion over a period of 1 hour.
Po rekonstituciji, filtriranju s priloženim filtrom in nadaljnjem redčenju se zdravilo MEPACT aplicira v obliki enourne intravenske infuzije.
After reconstitution, from a microbiological point of view, the product should be used immediately.
Po pripravi raztopine je zaradi mikrobioloških razlogov priporočena takojšnja uporaba zdravila.
After reconstitution, from a microbiological point of view, the solution should be used immediately.
Z mikrobiološkega vidika je treba zdravilo uporabiti takoj po rekonstituciji.
After reconstitution, immediate use is recommended.
Po raztapljanju (rekonstituciji) priporočamo takojšnjo uporabo.
After reconstitution, immediate use is recommended.
Priporoča se uporabiti zdravilo takoj po rekonstituciji.
After reconstitution, immediate use of the medicine is recommended.
Po rekonstituciji (pripravi za uporabo) je priporočljiva takojšnja uporaba.
After reconstitution, immediate useis recommended.
Zdravilo je priporočljivo uporabiti takoj po rekonstituciji.
After reconstitution, InductOs contains 1.5 mg/ml dibotermin alfa.
Po rekonstituciji vsebuje 1,5 mg/ml dibotermina alfa.
After reconstitution, it is recommended to inject the vaccine promptly.
Priporočljivo je, da se cepivo po rekonstituciji nemudoma injicira.
After reconstitution, it should be used within 4 hours at room temperature or 24 hours when stored at 2°C to 8°C.
Po rekonstituciji je treba pri sobni temperaturi zdravilo uporabiti v 4 urah, če je shranjeno pri temperaturi od 2 °C do 8 °C, pa v 24 urah.
After reconstitution, Omnitrope is given as an injection under the skin.
Po pripravi se zdravilo Omnitrope injicira pod kožo.
After reconstitution, one dose (0.5 ml) contains: The active substances are:
Po pripravi en odmerek (0,5 ml) vsebuje: Zdravilne učinkovine so:
After reconstitution, one ml of solution contains 100 Units of velaglucerase alfa
Po rekonstituciji en ml raztopine vsebuje 100 enot velagluceraze alfa.
After reconstitution, one vial contains 1.3 mg somatropin* (corresponding to 4 IU) per ml.
Po rekonstituciji ena viala vsebuje 1,3 mg somatropina* (ustreza 4 i.e.) na ml.
After reconstitution, one vial contains 500 Units (U) of C1 inhibitor (human) per 5 ml.
Po rekonstituciji vsebuje ena viala 500 enot (e.) zaviralca C1 (humanega) na 5 ml.
After reconstitution, one vial contains 500 Units of C1 inhibitor (human) per 5 ml corresponding to a concentration of 100 Units/ml.
Po rekonstituciji ena viala vsebuje 500 enot zaviralca C1 (humanega) na 5 ml, kar ustreza koncentraciji 100 enot/ml.
After reconstitution, one vial contains 500 Units of C1 inhibitor (human) per 5 ml corresponding to a concentration of 100 Units/ml.
Po rekonstituciji vsebuje ena viala 500 enot zaviralca C1 (humanega) na 5 ml, kar ustreza koncentraciji 100 enot/ml.
After reconstitution, PhotoBarr is a dark red to reddish brown, opaque solution.
Po pripravi je PhotoBar temno rdeča do rdečkastorjava motna raztopina.
After reconstitution, PhotoBarr solution should be protected from light and used immediately (within 3 hours).
Po pripravi je treba PhotoBarr zaščititi pred svetlobo in uporabiti v 3 urah.
After reconstitution, PhotoBarr solution should be protected from light and used immediately (within 3 hours).
Po pripravi je treba raztopino PhotoBarra zaščititi pred svetlobo in uporabiti v 3 urah.
After reconstitution, promptly dilute vials and do not store for subsequent use.
Raztopino, pripravljeno z vodo za injekcije, takoj razredčite in je ne shranite za naslednjo uporabo.
After reconstitution, protect from light and use immediately within 3 hours.
Po pripravi zaščitite zdravilo pred svetlobo in uporabite v 3 urah.
After reconstitution, store at 15 C – 25 C and use within 5 hours.
Po rekonstituciji, shranjujte pri temperaturi med 15˚C –in 25˚C in uporabite v manj kot 5 urah.
After reconstitution, store below 25 °C for 10 days
Po rekonstituciji shranjujte do 10 dni pri temperaturi do 25 C
After reconstitution, store below 25 °C for 10 days or in a refrigerator (2 °C - 8 °C) for 17 days
Po rekonstituciji shranjujte do 10 dni pri temperaturi do 25 C ali do 17 dni v hladilniku (2 C – 8 C)
After reconstitution, store below 25 °C for 10 days or in a refrigerator (2 °C - 8 °C) for 17 days.
Po rekonstituciji shranjujte do 10 dni pri temperaturi do 25 C ali do 17 dni v hladilniku (2 C – 8 C).
After reconstitution, store below 25 °C for 10 days or in a refrigerator (2 °C – 8 °C) for 17 days.
Po rekonstituciji shranjujte do 10 dni pri temperaturi do 25 °C ali do 17 dni v hladilniku (2 C – 8 C).
After reconstitution, store below 25 °C for 10 days.
Po rekonstituciji shranjujte do 10 dni pri temperaturi do 25 C.
After reconstitution, store the prepared oral solution in a refrigerator (2°C - 8°C) for 30 days.
Po rekonstituciji pripravljeno peroralno raztopino shranjujte v hladilniku (2 °C - 8 °C) največ 30 dni.
After reconstitution, the concentrate must be further diluted within 15 minutes using cold infusion fluids.
Koncentrat je treba razredčiti s hladno infuzijsko tekočino v 15 minutah po rekonstituciji.
After reconstitution, the concentration of parecoxib is 20 mg/ml.
Koncentracija parekoksiba po pripravi raztopine je 20 mg/ml.
After reconstitution, the liquid should be a clear solution.
Po pripravi mora biti tekočina bistra raztopina.
After reconstitution, the medicinal product should be used immediately due to the risk of microbiological contamination.
Po pripravi je treba zdravilo zaradi tveganja za mikrobiološko kontaminacijo uporabiti takoj.
After reconstitution, the product contains 1 mg/ml eptacog alfa (activated) and 10 mg/ml sucrose when reconstituted with solvent.
Po rekonstituciji s topilom vsebuje zdravilo 1 mg/ml aktiviranega eptakoga alfa in 10 mg/ml saharoze.
After reconstitution, the product should be used immediately.
Rekonstituirano cepivo je treba uporabiti takoj.
After reconstitution, the reconstituted solution should be inspected visually for extraneous (or for any foreign) particulate matter or any variation in physical appearance prior to administration.
Po rekunstrukciji je treba pripravljeno raztopino pred uporabo vizualno pregledati, da ne vsebuje tujih delcev oz. se njen fizični izgled ni spremenil.
After reconstitution, the reconstituted solution should be transferred from the vial to the infusion bag or bottle immediately.
Priporočljivo je, da se po pripravi raztopine, raztopino iz viale takoj prenese v infuzijsko vrečo ali steklenico.
After reconstitution, the reconstituted suspension in the infusion bag should be used immediately.
Po rekonstituciji morate suspenzijo v infuzijski vrečki takoj uporabiti.
After reconstitution, the solution contains 40 units of imiglucerase per ml.
Po rekonstituciji vsebuje raztopina 40 enot imigluceraze na ml.
After reconstitution, the solution contains 5 mg of alglucosidase alfa* per ml and after dilution, the concentration varies from 0.5 mg to 4 mg/ml.
Po rekonstituciji raztopina vsebuje 5 mg alglukozidaze alfa* na ml in po redčenju koncentracija niha od 0,5 mg do 4 mg/ml.
After reconstitution, the solution contains 80 mg belimumab per ml.
Po rekonstituciji ml raztopine vsebuje 80 mg belimumaba.
After reconstitution, the solution is drawn back into the syringe.
Po rekonstituciji raztopino potegnite nazaj v brizgo.
After reconstitution, the solution is drawn back into the syringe.
Pripravljeno raztopino povlecite nazaj v brizgo.
After reconstitution, the solution should be injected within three hours.
Po rekonstituciji morate raztopino zdravila Thyrogen injicirati v treh urah.
After reconstitution, TruScient solution contains 0.2 mg/ml of dibotermin alfa (rhBMP-2).
Po rekonstituciji raztopina zdravila TruScient vsebuje 0,2 mg/ml dibotermina alfa (rhBMP-2).
After reconstitution, use immediately or within 8 hours if stored in a refrigerator
Po pripravi uporabite takoj ali v 8 urah, če ste shranjevali v hladilniku.
After reconstitution, use immediately.
Uporabite takoj po rekonstituciji.
After reconstitution, use the reconstituted solution immediately or within 24 hours when stored in a refrigerator (2°C - 8°C).
Po rekonstituciji uporabite rekonstituirano raztopino takoj ali v roku 24 ur, če ste jo medtem shranili v hladilniku (2 °C – 8 °C).
After reconstitution, use within 21 days.
Po rekonstituciji porabite v 21 dneh.
After reconstitution, use within 24 hours.
Po rekonstituciji porabite v 24 urah.
After reconstitution, use within 28 days.
Rekonstituirano zdravilo porabite v 28 dneh.
After reconstitution,1 dose (0.5 ml) contains:
Po pripravi cepiva 1 odmerek (0,5 ml) vsebuje:
After reconstitution:
Po rekonstituciji
After reconstitution: 24 hours at 2 °C – 8 °C, protected from light.
Po pripravi: 24 ur pri temperaturi med 2 °C in 8 °C, zaščiteno pred svetlobo.